Can I Take Folate with AndroGel?

What AndroGel Is and How It Works

AndroGel is a transdermal testosterone gel approved by the FDA for male hypogonadism, defined as serum testosterone below 300 ng/dL on two morning measurements accompanied by clinical symptoms such as low libido, fatigue, or reduced muscle mass. The 1% formulation (5 g gel delivering 50 mg testosterone) and the 1.62% formulation (2.5 to 10 g gel delivering 40.5 to 81 mg testosterone) are both available by prescription and are applied once daily to shoulders, upper arms, or abdomen.

Testosterone absorbs transdermally, enters systemic circulation, and is converted peripherally to dihydrotestosterone (DHT) via 5-alpha-reductase and to estradiol via aromatase. Peak serum concentrations typically occur 2 hours after application. The FDA-approved label targets a serum testosterone range of 300 to 1,000 ng/dL.

What Folate Is and Why Men Take It

Folate is the naturally occurring B-vitamin found in leafy greens, legumes, and liver. Folic acid is the synthetic oxidized form used in supplements and fortified foods. 5-methyltetrahydrofolate (5-MTHF, sold as Metafolin or Quatrefolic) is the biologically active reduced form that cells actually use.

Men supplement folate for several reasons: to support red-blood-cell synthesis, to lower homocysteine (a cardiovascular risk marker), to support spermatogenesis, and, in the case of MTHFR gene variants, to compensate for impaired endogenous folate conversion. The recommended dietary allowance (RDA) for adult men is 400 mcg DFE per day, established by the National Institutes of Health Office of Dietary Supplements.

Why This Combination Comes Up Clinically

Men starting testosterone replacement therapy (TRT) often review their supplement regimens at the same appointment. Folate is one of the most commonly taken supplements in the U.S. Adult population. A 2017 National Health and Nutrition Examination Survey (NHANES) analysis found that approximately 22% of adult men reported taking a folic-acid-containing supplement in the prior 30 days. When providers prescribe AndroGel, patients naturally ask whether their existing supplements are safe to continue.

Is There a Direct Drug-Supplement Interaction?

No direct pharmacokinetic interaction between testosterone gel and folate has been identified in published clinical literature or in the FDA-approved labeling for AndroGel. Testosterone is metabolized primarily by hepatic CYP3A4 and secondarily by other cytochrome P450 enzymes. Folate is not a substrate, inhibitor, or inducer of CYP3A4 at physiological or standard supplemental doses. The two compounds do not share transport proteins, plasma protein binding sites, or renal excretion pathways in any clinically meaningful way.

The Natural Medicines database (referenced in the competitor context as a standard interaction-checking resource) does not list a direct interaction between testosterone and folic acid or 5-MTHF as of current published summaries.

Pharmacodynamic Overlap: Where Attention Is Warranted

Even without a pharmacokinetic interaction, the two substances touch overlapping physiological pathways.

Homocysteine and cardiovascular risk. Testosterone therapy can raise hematocrit and, in some patients, mildly raise homocysteine. Folate is the primary nutritional driver of homocysteine remethylation back to methionine via the one-carbon methylation cycle. Low folate status leads to homocysteine accumulation. An analysis of 1,980 adults in the Framingham Heart Study cohort found that for every 3 mcg/dL increase in plasma folate, homocysteine fell by approximately 1 µmol/L. Men on TRT who have borderline folate status may therefore benefit from supplementation to keep homocysteine in the normal range (<15 µmol/L is the widely used clinical threshold) [1].

Red-blood-cell production. Both testosterone and folate stimulate erythropoiesis, though through different mechanisms. Testosterone increases erythropoietin production; folate is required for DNA synthesis in rapidly dividing red-cell precursors. Combined, the theoretical concern is an additive rise in hematocrit. The AndroGel prescribing information states that hematocrit should be checked at 3 to 6 months after starting therapy and annually thereafter, with dose reduction or phlebotomy considered if hematocrit exceeds 54%. In practice, folate-driven erythropoiesis is substrate-limited rather than stimulatory, meaning folate corrects deficiency-related anemia but does not drive hematocrit above normal in replete patients. Still, checking a CBC at baseline is prudent when starting both [2].

Sperm quality data. A 2014 Cochrane review of antioxidant supplementation in male infertility (N=2,876 men across 48 trials) found that folate combined with zinc improved sperm concentration and motility in some subgroups, but this is only relevant for men on TRT who are simultaneously attempting fertility preservation, a combination that requires separate clinical management because exogenous testosterone suppresses intratesticular testosterone and can impair spermatogenesis [3].

MTHFR Variants and Testosterone Therapy

Roughly 10 to 15% of people of Northern European descent carry two copies of the MTHFR C677T polymorphism (homozygous TT genotype), which reduces the activity of the methylenetetrahydrofolate reductase enzyme by approximately 70% compared to the CC genotype. This impairs the conversion of dietary folate to 5-MTHF, the active form that donates methyl groups for homocysteine remethylation and DNA methylation.

Why MTHFR Matters More on TRT

Testosterone therapy has been associated with modest elevations in homocysteine in some short-term studies. A 2001 study by Zmuda et al. Published in Metabolism (N=58 older men receiving testosterone enanthate 200 mg every 2 weeks for 36 months) found no significant change in homocysteine at the doses used, but the population had normal MTHFR function [4]. Men with the homozygous TT genotype start with a biochemical disadvantage in homocysteine clearance. Adding a testosterone stimulus, even a modest one, could push homocysteine higher in that subgroup.

Which Form of Folate to Use if You Have MTHFR C677T

Folic acid (the synthetic form) requires a two-step enzymatic reduction to become 5-MTHF. In TT-genotype individuals, this conversion is impaired. The clinically preferred approach for MTHFR C677T carriers is to use 5-MTHF directly, bypassing the rate-limiting enzyme. Methylfolate supplements (400 to 1,000 mcg 5-MTHF per day) achieve equivalent or higher plasma folate concentrations compared to folic acid at the same molar dose in TT carriers, based on a crossover pharmacokinetic study by Prinz-Langenohl et al. (N=40) [5].

For men without MTHFR variants, standard folic acid at 400 to 800 mcg/day is adequate and significantly less expensive.

Folate Dosing Alongside AndroGel: A Practical Framework

The table below gives a structured approach based on a patient's clinical profile. These are starting points for shared decision-making, not prescriptions.

| Clinical Profile | Recommended Folate Form | Dose Range | Monitoring | |---|---|---|---| | No MTHFR variant, normal homocysteine | Folic acid or food-first | 400 mcg DFE/day | Homocysteine annually | | MTHFR C677T heterozygous (CT), homocysteine <15 µmol/L | 5-MTHF preferred | 400 to 800 mcg/day | Homocysteine at 3 months, then annually | | MTHFR C677T homozygous (TT), any homocysteine | 5-MTHF required | 800 to 1,000 mcg/day | Homocysteine at 3 months; CBC at 6 months | | Elevated homocysteine (>15 µmol/L) at baseline | 5-MTHF + B12 co-supplementation | Up to 5 mg/day folate (Rx-level) | Homocysteine monthly until stable | | Also on valproate or phenytoin | Folic acid or 5-MTHF | 1 to 5 mg/day (discuss with neurologist) | Homocysteine, CBC every 3 months |

The 5 mg therapeutic dose of folic acid is available by prescription and is used in clinical practice for drug-induced folate depletion and hyperhomocysteinemia. It should be managed alongside the prescribing neurologist if anticonvulsants are involved.

Anticonvulsants, Folate Depletion, and AndroGel

This combination is the one scenario where folate supplementation becomes medically indicated rather than optional. Valproic acid (Depakote) and phenytoin (Dilantin) both deplete folate through distinct mechanisms: valproate inhibits dihydrofolate reductase and accelerates folate catabolism; phenytoin interferes with intestinal folate absorption and also accelerates hepatic folate metabolism.

Men with epilepsy who are prescribed AndroGel for hypogonadism may thus be on three substances simultaneously. The American Epilepsy Society and multiple neurology guidelines recommend folate supplementation at 1 to 5 mg/day for patients on folate-depleting anticonvulsants, primarily to reduce neural tube defect risk in women of reproductive age, but the metabolic rationale applies to men as well given the cardiovascular implications of elevated homocysteine.

A 2010 meta-analysis by Apeland et al. In Epilepsia reviewed homocysteine levels in 1,788 patients on antiepileptic drugs and found that valproate users had a mean homocysteine of 12.4 µmol/L vs. 8.6 µmol/L in controls, a difference associated with folate depletion [6]. If you take valproate or phenytoin alongside AndroGel, discuss folate dosing with both your prescriber and your neurologist.

What the FDA Label Says and What It Does Not

The AndroGel prescribing information (most recent label revision on FDA.gov) lists the following interaction categories: insulin (testosterone may reduce insulin resistance), anticoagulants such as warfarin (testosterone may potentiate anticoagulant effects), and corticosteroids (additive edema risk). Folate is not mentioned in the drug-interaction section of the label because no clinically significant pharmacokinetic interaction has been identified [7].

The boxed warning in the label addresses secondary exposure (children and women absorbing testosterone from skin-to-skin contact) and is unrelated to supplement interactions.

What to Tell Your Prescriber

When your provider reviews your AndroGel prescription, disclose all supplements, including folate, multivitamins containing folic acid, and any methylfolate products. The prescriber needs:

1. The specific form of folate (folic acid vs. 5-MTHF vs. Folinic acid).
2. The dose in micrograms or milligrams per day.
3. Whether you have been tested for MTHFR variants.
4. Your most recent homocysteine level, if available.

This information lets the provider tailor the monitoring schedule rather than ordering redundant tests.

Monitoring Schedule When Taking Both

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends checking hematocrit at 3 to 6 months after initiation and at 12 months, then annually. Serum testosterone should be checked 2 weeks after the first dose adjustment and then at each subsequent visit. These are the minimum checkpoints; adding folate to the regimen does not require additional office visits but does argue for including homocysteine and B12 in the baseline metabolic panel [8].

Specific Lab Targets

• Hematocrit: below 54% (Endocrine Society threshold for dose reduction or phlebotomy).
• Serum testosterone: 300 to 1,000 ng/dL, with most men feeling best between 400 to 700 ng/dL.
• Homocysteine: below 15 µmol/L; below 10 µmol/L is optimal by most cardiological consensus.
• Serum folate: above 4 ng/mL (above 7 ng/mL is preferred for MTHFR TT carriers).
• Vitamin B12: above 300 pg/mL; folate repletion without adequate B12 can mask B12 deficiency.

The Endocrine Society states: "Clinicians should check a hematocrit before initiating testosterone therapy, at 3 to 6 months, and then annually. If the hematocrit is >54%, stop therapy until the hematocrit decreases to a safe level, evaluate the patient for hypoxia and sleep apnea, and reinitiate therapy with a reduced dose" [8].

Timing and Dose Separation

No dose-separation window is required between AndroGel application and folate ingestion. The two are absorbed through entirely different routes (transdermal vs. Oral/gastrointestinal) and do not compete for the same transporters. Apply AndroGel at the same time each morning, let it dry for 3 to 5 minutes, wash hands thoroughly, and take your folate supplement whenever it is most consistent with your daily routine.

Some patients prefer to take B-vitamins, including folate, with a meal to reduce any gastrointestinal discomfort from folic acid tablets. This is a convenience consideration, not a pharmacokinetic one.

Evidence on Folate and Male Cardiovascular Health in TRT Context

TRT in older men has been the subject of renewed cardiovascular scrutiny since the TRAVERSE trial (N=5,246 men aged 45 to 80 with hypogonadism and elevated cardiovascular risk) published in the New England Journal of Medicine in 2023. TRAVERSE found no significant difference in major adverse cardiovascular events (MACE) between testosterone-treated and placebo groups over a mean follow-up of 22 months (hazard ratio 0.96, 95% CI 0.78 to 1.17), providing some reassurance about cardiovascular safety in this population [9].

Separately, a 2017 Cochrane review by Martí-Carvajal et al. On homocysteine-lowering interventions for preventing cardiovascular events (N=39,195 participants across 15 trials) found that folic acid supplementation lowered homocysteine by a mean of 25% but did not significantly reduce myocardial infarction or all-cause mortality. Stroke risk was reduced by 10% (RR 0.90, 95% CI 0.82 to 0.99), a modest but real signal [10].

The practical implication: folate supplementation is unlikely to dramatically alter the cardiovascular risk profile of a man on AndroGel, but it may provide a small benefit in men with elevated baseline homocysteine, particularly those with MTHFR TT genotype.

Polycythemia Risk: Reading the Evidence Carefully

Testosterone-induced erythrocytosis (hematocrit >54%) is the most common dose-limiting adverse effect of TRT, occurring in roughly 10 to 20% of patients depending on the formulation and dose. The theoretical concern about folate's additive effect on red-cell production is worth examining.

In iron-deficient or folate-deficient patients, adding folate can raise hematocrit toward normal. In patients who are already folate-replete, adding more folate does not further raise hematocrit because erythropoiesis is erythropoietin-limited at that point, not substrate-limited. The distinction is important: folate is not erythropoietin. It supplies a building block. Without the hormonal signal, extra folate does not produce extra red cells.

Men starting AndroGel with a hematocrit above 50% may want to confirm folate and B12 adequacy before adding supplements, simply to ensure any existing erythrocytosis is not being amplified by a concurrent deficiency correction. A hematocrit above 52% before starting TRT may warrant a hematology consultation regardless of supplement use.

Special Populations

Men Over 65

Older men are more likely to have reduced gastric acid production (atrophic gastritis), which impairs folic acid absorption. They are also more likely to have borderline B12 deficiency. In this group, 5-MTHF is a better choice than folic acid, and B12 supplementation (500 to 1,000 mcg cyanocobalamin or methylcobalamin daily) should accompany folate to prevent the unmasking of B12 deficiency by folate repletion.

Men with Chronic Kidney Disease

Chronic kidney disease (CKD) is both a common comorbidity in men seeking TRT and a cause of elevated homocysteine due to impaired renal folate conservation. The National Kidney Foundation's KDOQI guidelines historically recommended folate supplementation in dialysis patients to control homocysteine, though the cardiovascular benefit of homocysteine lowering in CKD remains debated. Men on AndroGel who also have CKD stages 3 to 5 should have homocysteine and folate levels checked before starting either supplement.

Men Pursuing Fertility While on Testosterone

This is a contraindication-adjacent situation. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing FSH and LH, and can cause azoospermia within 3 to 4 months of starting TRT. If fertility is a current goal, androgen therapy is generally avoided in favor of clomiphene citrate, hCG, or FSH injections. In that context, folate at 400 to 800 mcg/day supports spermatogenesis and is actively beneficial. The supplement question changes completely once the primary therapy changes.